6:29 PM
 | 
Jan 28, 2016
 |  BC Extra  |  Company News

Neos rises after ADHD approval

Neos Therapeutics Inc. (NASDAQ:NEOS) gained $3.96 (42%) to $13.38 on Thursday after FDA approved Adzenys XR-ODT ( NT-0202) to...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >